store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lumiracoxib (Prexige) 是强选择性有口服活性的 COX-2抑制剂,Ki 值为 0.06 μM。它是非选择性非甾体抗炎试剂,具有抗炎和解热活性,可用于骨关节炎和骨癌研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 278 | 现货 | ||
10 mg | ¥ 393 | 现货 | ||
25 mg | ¥ 659 | 现货 | ||
50 mg | ¥ 987 | 现货 | ||
100 mg | ¥ 1,690 | 现货 | ||
200 mg | ¥ 2,520 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 460 | 现货 |
产品描述 | Lumiracoxib (Prexige) is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. Phase 4. |
靶点活性 | COX-2 (cell-free assay):Ki:60 nM, COX-1 (cell-free assay):Ki:3 μM |
体外活性 | Lumiracoxib has an IC50 of 0.14 μm in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 μm (HEK 293 cells transfected with human COX-1). In a human whole blood assay, IC50 values for Lumiracoxib are 0.13 μM for COX-2 and 67 μM for COX-1 (COX-1/COX-2 selectivity ratio 515). |
体内活性 | Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety. Lumiracoxib is rapidly absorbed following oral administration in rats with peak plasma levels being reached between 0.5 and 1 h. Efficacy of Lumiracoxib in rat models of hyperalgesia, oedema, pyresis and arthritis is dose-dependent and similar to diclofenac. However, consistent with its low COX-1 inhibitory activity, Lumiracoxib at a dose of 100 mg/kg orally causes no ulcers and is significantly less ulcerogenic than diclofenac. |
动物实验 | Animal Models: Female Lewis ratsFormulation: Sterile phosphate-buffered salineDosages: 0.2–2 mg/kgAdministration: Oral gavage |
别名 | Prexige, 罗美昔布, COX-189 |
分子量 | 293.72 |
分子式 | C15H13ClFNO2 |
CAS No. | 220991-20-8 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 55 mg/mL (187.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.4046 mL | 17.023 mL | 34.046 mL | 85.1151 mL |
5 mM | 0.6809 mL | 3.4046 mL | 6.8092 mL | 17.023 mL | |
10 mM | 0.3405 mL | 1.7023 mL | 3.4046 mL | 8.5115 mL | |
20 mM | 0.1702 mL | 0.8512 mL | 1.7023 mL | 4.2558 mL | |
50 mM | 0.0681 mL | 0.3405 mL | 0.6809 mL | 1.7023 mL | |
100 mM | 0.034 mL | 0.1702 mL | 0.3405 mL | 0.8512 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lumiracoxib 220991-20-8 Immunology/Inflammation Neuroscience COX Prexige Cyclooxygenase Inhibitor 罗美昔布 bone cancer osteoarthritis COX 189 inflammatory COX189 inhibit hyperalgesic COX-189 Metabolic Syndrome inhibitor